Kent Davies Joins Haemonetics as President, Global Markets
BRAINTREE, Mass., April 30, 2014 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that Kent J. Davies will join the Company effective May 12, 2014 as President, Global Markets. Mr. Davies will join Haemonetics as a member of the Executive Council and Operating Committee, assuming responsibility for worldwide oversight of all of the Company's commercial operations, except the Global Plasma business. In this role, Mr. Davies will have responsibility for business elements representing 70% of Haemonetics' revenue base, as he leads the company to pursue consistent and profitable growth in its worldwide markets.
Brian Concannon, Haemonetics' President and CEO, commented: "We are delighted that Kent will be joining our team to help us execute our unique blood management vision. He brings a wealth of experience from successful leadership roles with rapidly-growing public and private businesses, and he has had considerable success driving profitable growth in the global markets in which we operate. We wanted a dynamic, results-oriented leader with a strong healthcare background, who has consistently delivered growth, strategic transformation and strong financial performance while remaining focused on customer needs. Kent brings all of that, with a unique personal perspective, presence, and sense of urgency developed through 25 years of multi-functional business development experience in the U.S., Europe, and emerging markets."
Mr. Davies, age 50, was most recently the CEO of RoundTable Healthcare Partners' RoundTable III Platform Development Corporation ("RPDC"). In this role, Mr. Davies focused on the identification and development of new investment opportunities in the medical device market. Prior to RPDC, Mr. Davies held executive roles of increasing responsibility including CEO of Gaymar Industries, a privately-held medical device and equipment company acquired by Stryker Corp., Division President and corporate officer of publicly-traded Solutia, Inc., as well as a variety of global general management, commercial, and product leadership roles with Kimberly-Clark Healthcare and 3M Healthcare. Mr. Davies brings a strong balance of commercial, operational, financial and change leadership skills to Haemonetics.
Mr. Davies holds a BA from the University of California, Berkeley, an MBA from the University of Minnesota, and has completed advanced course work in Finance at The Wharton School at the University of Pennsylvania.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
Alt. (781) 356-9613
SOURCE Haemonetics Corporation